HOME >> BIOLOGY >> NEWS
New antibacterials being developed to tackle MRSA superbug

A novel antibacterial medicine that kills the superbug MRSA is being developed under a new scheme launched by the Wellcome Trust. The Seeding Drug Discovery initiative is aimed at catalysing the development of new drugs in areas of unmet need.

Prolysis, an R&D company based in Oxford, has received one of three inaugural Seeding Drug Discovery awards for its new antibacterial compounds aimed at tackling life-threatening, drug-resistant infections caused by staphylococci, including MRSA.

The bacterium Staphylococcus aureus can infect wounds, including those resulting from medical procedures conducted in hospitals. It may then spread further into the body and cause serious infections such as blood poisoning. Methicillin-resistant Staphylococcus aureus, or MRSA, is a form of the bacterium that is resistant to the drug methicillin and a number of other antibiotics and tends to be more difficult to treat.

"The so-called superbug MRSA is fast becoming untreatable with the currently available antibiotics," says Dr Ted Bianco, Director of Technology Transfer at the Wellcome Trust. "We urgently need a new generation of antibacterial medicines to stop its spread through hospitals, nursing homes and the wider community."

The compounds being developed by Prolysis under the award from the Wellcome Trust block the ability of the MRSA bacteria to divide and multiply. They do this by inhibiting the function of the bacterium's FtsZ protein, which is essential for cell division. FtsZ is not found in humans so targeting a unique protein like this should reduce the likelihood of side-effects in patients. Because of the novel mode of action of the new class of compounds, the levels of resistance in the bacterial population should be extremely low if a new drug was to emerge from this programme.

"The antibiotic that we are developing is far more selective than those currently in use, targeting only staphylococcal infections," says Dr Lloyd
'"/>

Contact: Craig Brierley
c.brierley@wellcome.ac.uk
44-207-611-7329
Wellcome Trust
14-Jan-2007


Page: 1 2

Related biology news :

1. Universal flu vaccine being tested on humans
2. Reproductive speed protects large animals from being hunted to extinction
3. DNA layer reduces risk of reserve parts being rejected
4. Are scientists making progress in being able to regenerate bone tissue?
5. Its not easy being green
6. Its not easy being green
7. Accelerating loss of ocean species threatens human well-being
8. Accelerating loss of ocean species threatens human well-being
9. Fat stem cells being studied as option for breast reconstruction
10. Nanotechnology being used to improve biocompatibility of human prosthetics and implants
11. Progress being made in exploring potential use of stem cells to treat heart disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/7/2018)... ... September 05, 2018 , ... ... mAb manufacturing facility late last year, IPS-Integrated Project Services, LLC and G-CON Manufacturing ... autologous cell therapies. The iCON solution provides a pre-fabricated modular cleanroom infrastructure for ...
(Date:8/31/2018)... ... August 30, 2018 , ... CallTower is pleased to announce Jason ... of telecommunications experience and over ten years in executive leadership. Prior to joining CallTower, ... in early 2018. , In this new role, Jason will manage ...
(Date:8/29/2018)... CAMBRIDGE, Mass. (PRWEB) , ... August 28, 2018 ... ... QipWorks, today introduced an annual awards program that recognizes women of excellence in ... recipient. , Sponsored by QipWorks, the Johanna Dwyer Women in IP Award aims ...
Breaking Biology News(10 mins):
(Date:9/7/2018)... ... September 06, 2018 , ... ... and commercialization, is releasing the agenda for its upcoming user conference. , ... industries discussing the latest challenges, opportunities, and approaches to regulatory compliance and quality ...
(Date:9/1/2018)... ... August 31, 2018 , ... ... of the impact of a proprietary biofield energy treated nutraceutical supplement used in ... for immune function response and blood, as well as, organ-specific inflammation. The reported ...
(Date:8/29/2018)... , ... August 28, 2018 , ... ... enhanced spinal implants, announced today the successful completion of a $5.5 million funding ... Corporation, Purdue’s Foundry Investment Fund, Commenda Capital, and Ellipsis Ventures. , “Our investment ...
(Date:8/29/2018)... ... August 28, 2018 , ... CEO and founder ... safety study performed on an allogeneic (donor derived) stem cell product for osteoarthritis ... conference in September. He is also the organizer of Breakout Session 4: ...
Breaking Biology Technology:
Cached News: